

LUNG DISEASE SITE COMMITTEE MEETING

CHELSEA HOTEL, TORONTO, ON
ROOM: CHURCHILL BALLROOM A
SATURDAY MAY 4, 2024, 1:30 PM – 4:00 PM

CO-CHAIRS : PENELOPE BRADBURY, ALEX SUN
SENIOR INVESTIGATOR: PIERRE-OLIVIER GAUDREAU

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to the management of lung cancer
- To cite and analyze recent results of lung cancer clinical studies conducted by or in collaboration with the Canadian Cancer Trials Group

1:30 pm	Welcome and Introduction	P. Bradbury / A. Sun
1:35 pm	<u>BR.31:</u> A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected NSCLC	G. Goss
1:45 pm	<u>IND.242</u> Neoadjuvant Platform Trial in Patients with Surgically Resectable Non-Small Cell Lung Cancer	J. Spicer
2:00 pm	<u>IND.227:</u> A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (Phase II results and Phase III update)	Q. Chu
2:10 pm	<u>BRC.7 (ECOG-ACRIN EA5163), INSIGNA:</u> A Randomized, Phase III Study of First line Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post Progression in Advanced Non-squamous NSCLC with Immunobiomarker SIGNature-driven Analysis	A. Robinson
2:20 pm	<u>BRC8 (S1827), MAVERICK:</u> A Randomized Phase III Trial of MRI Surveillance with or without Prophylactic Cranial Irradiation in SCLC	A. Sun
2:30 pm	<u>IND.238:</u> A Phase II Study of Durvalumab Substudy A: In Patients who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity Substudy B: For Continued Treatment (+/-) Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies	P. Ellis
2:40 pm	Break	
2:50 pm	<u>Proposals in Development</u>	
	<u>BR.36 (CRI-CCTG-0002):</u> A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer	S. Moore
3:10 pm	<u>BR.38 (CURB2):</u> Consolidative Use of Radiotherapy to Block (CURB2) Oligoprogression in Patients with Metastatic Non-Small-Cell Lung Cancer	J. Tsai
3:30 pm	<u>New proposals</u>	
4:00 pm	Meeting adjourned	

